Dechra Pharmaceuticals sees 50 per cent leap in revenue

3rd Sep 2013 14:56

Veterinary pharmaceuticals group Dechra Pharmaceuticals experienced a 'momentous' year with a 52.2 per cent jump in total revenue. Turnover from both continued and discontinued operations climbed from £440m to £522.4m, while underlying pre-tax profit rose from £32.9m to £44.6m. The underlying diluted earnings per share jumped from 32.27p to 38.71p. The dividend was boosted by 14.1% to 14p per share. Chief Executive Officer Ian Page said: "Strategically it has been a momentous year with the successful integration of Eurovet, acquired in May 2012, and with the transformational effect of the £87.5m divestment of the Services businesses. "Dechra is now entirely focused on developing, manufacturing and marketing high margin, cash generative specialist veterinary pharmaceuticals and related products for global markets."NR